Nvidia’s Q3 FY27: The Reassurance Before the Storm
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
Nvidia faces allegations over China and Southeast Asia sales, financial reporting and governance ahead of Q3 FY27 results.
@evfcfaddict @alluvialcapital $BWEL will work eventually
Tom likes the stock. $MKL adding >10% buyback auth, now ~15% buyback auth outstanding.
Target Posts Strongest Sales Growth in Years as Focus on New Products, Value Pays Off $TGT
Nvidia faced China workaround enforcement concerns as technology fell 6%; energy rose 4.5%, while the company raised eFY28 revenue growth…
MiniMed's 15.8% Q1 organic growth and 20% U.S. pump-volume increase support a product-cycle recovery as split-off selling fades.
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and guided $130 billion, while Jensen Huang’s resignation left Colette Kress as…
Pfizer’s Q3 revenue reached $16.58 billion, launched and acquired products grew 32%, and FY26 guidance rose to $62 billion to $64 billion.
NVIDIA’s fiscal third-quarter 2027 results are its first earnings report since Jensen Huang’s resignation as CEO.
UFP Industries trades near its 2022 price despite EPS falling 62%; a $95–$105 valuation assumes $6.30 normal-year EPS, with freight and…
Nvidia reported $115.8 billion in Q3 revenue, up 103%, and raised its fiscal 2028 growth outlook to 75% as interim CEO Colette Kress…
Century Aluminum (CENX) could benefit from U.S. tariffs, Midwest aluminum premiums and constrained global supply, with the stock trading…
Figma grew Q3 revenue 43% to $391.4 million, raised FY2026 guidance to nearly $1.5 billion and guided Q4 above consensus despite the stock…
Nvidia raised its fiscal 2028 growth outlook, but shares reversed as investors focused on uncertainty beyond January 2028.
ZTS · long Zoetis, the animal prescription-medicines company, is presented as a long investment despite concerns around its 2026 and 2027 outlook.
Frequency Electronics ($FEIM) trades at its lowest EV/EBITDA multiple since 2016 despite satellite-timing exposure to Golden Dome spending…
Pharma-Bio Serv’s $11 million market cap nearly matches its $10.7 million cash balance as recovering life-sciences spending supports…
WNMLA trades near $4 versus estimated $8.95 NCAV, but loss-making fund management and cross-holdings leave value dependent on capital…
NSTS Bancorp’s three-year thrift-conversion anniversary could clear the way for a potential sale.
Envista, Danaher’s dental spin-off, is pitched as a de-risked long-term opportunity after U.S.
NLOP repaid 10% and 14.5% debt, leaving most properties unencumbered as office sales support a roughly $38.20 NAV per share.
Greg Abel becomes Berkshire Hathaway CEO on January 1, 2026, with Warren Buffett remaining chairman and involved in major opportunities.
Brookfield faces whistleblower allegations over its VC funds; $569 million of Q1 buybacks challenges claims that $8 million of remaining…
Every publication on this site, hand-picked.
Every account on this site, hand-picked.
Ordered by how often our editor reaches for them.